Genetic News and Research

RSS

GEN co-sponsored roundtable discussion on Gulf Oil Spill

Genetic Engineering & Biotechnology News announced that on Thursday, October 28th, they co-sponsored a roundtable discussion on new ways to use biological solutions to assist in environment cleanup after manmade or natural disasters.

2 Nov 2010

NanoString’s nCounter CNV CodeSets help detect genetic copy number variations

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the launch of a novel solution for detecting genetic copy number variations (CNVs) associated with disease susceptibility, drug response and cancer progression.

From NanoString Technologies 2 Nov 2010

Study explains statistical link between low aerobic exercise capacity and common diseases

Everybody knows that if you're physically fit, you're less likely to get a wide range of diseases. What most people don't know is that some people are "naturally" in better shape than others, and this variation in conditioning makes it difficult to test for disease risk and drug effectiveness in animal models.

2 Nov 2010

Autism Consortium begins new therapeutic initiative on Translational Medicine

The Autism Consortium, an innovative Boston area collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), announced that it will begin a new initiative on Translational Medicine and Autism Therapeutics. The new focus was introduced at the Consortium's fifth annual symposium held October 26th, 2010, at Harvard Medical School in Boston.

2 Nov 2010

ArcticDx develops test to determine inherited risk for AMD

Established in 2007 and based in Toronto, ArcticDx has developed a test, Macula Risk-, the first of its kind and specifically designed to determine one's inherited risk for age-related macular degeneration (AMD), the most common form of acquired blindness in the developed world, affecting over 10% of individuals. ArcticDx will use the PBDF investment to undertake studies in support of a planned filing for Food and Drug Administration (FDA) approval for Macula Risk.

2 Nov 2010

New targeted therapy shows positive results in patients with lung cancer

A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.

2 Nov 2010

NSAIDs drugs prevent colon cancer: Research

Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent colon cancer by triggering diseased stem cells to self-destruct, according to researchers at the University of Pittsburgh Cancer Institute (UPCI) and the University of Pittsburgh School of Medicine.

2 Nov 2010

New REACT medical trial for early diagnosis of lung cancer

Physicians at El Camino Hospital are starting a medical trial called REACT that they hope may give doctors a new and cost-effective tool for early diagnosis of lung cancer, the deadliest of the common cancers.

2 Nov 2010

GSN closes $12M Series C financing

Gene Security Network, Inc. today announced the closing of its $12M Series C financing. The financing round was led by Sequoia Capital and included Claremont Creek Ventures, Founders Fund, and Lightspeed Venture Partners.

2 Nov 2010

Einstein College's new website features latest information on aging research

Albert Einstein College of Medicine of Yeshiva University has launched SuperAgers.com, a new website that features the latest information on more than a decade of aging research at Einstein.

2 Nov 2010

Research on AID enzyme could improve therapy for lymphoma, leukemia

A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.

2 Nov 2010

Study finds increasing dosage of blood thinners can help cardiovascular disease patients with genetic defect

Cardiovascular disease patients who have a genetic defect that makes them less responsive to blood thinners may be helped with an increased dosage, according to results of an innovative pilot study led by a cardiologist at The University of Texas Health Science Center at Houston (UTHealth).

2 Nov 2010

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

Rubicon Genomics today reported data demonstrating that its PicoPlex kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing (NGS).

2 Nov 2010

Non-dividing cells can also start cancer

Cancer Research UK scientists have found that non-dividing cells are able to kick-start some cancers, challenging a long held belief that only dividing cells, like stem cells, cause the disease, according to research published online in PNAS today (Monday).

2 Nov 2010

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

Valeant Pharmaceuticals International, Inc. and Kadmon Pharmaceuticals LLC have concluded two strategic agreements for the development and commercialization of taribavirin and the commercial marketing of ribavirin in the treatment of viral diseases, including hepatitis C virus (HCV).

1 Nov 2010

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), a rare genetic disorder. This approval was for treatments of SEGA that can not be treated with surgery.

1 Nov 2010

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

Discovery Laboratories, Inc. today announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis (CF).

1 Nov 2010

Life Technologies announces launch of new sequencer to deliver genomic data

Life Technologies Corporation a provider of innovative life science solutions, today announced the launch of the 5500xl SOLiD Sequencer, a new instrument designed to deliver the industry's fastest and most accurate genomic data for cancer biology and genetic disease research.

1 Nov 2010

Study examines effects of social stimulation and personality on humans' sleep functions

A study in the Nov. 1 issue of the journal SLEEP found that vulnerability to sleep deprivation is influenced by the interaction between waking social activity and individual personality traits.

1 Nov 2010

Special issue of Ecopsychology outlines woman's self-perception and behavior

Women experience and interact with their natural surroundings in ways that differ from men. The way in which those differences affect a woman's sense of self, body image, and drive to protect and preserve the environment are explored in a thought-provoking special issue of Ecopsychology, a peer-reviewed, online journal published by Mary Ann Liebert, Inc.

30 Oct 2010